Appili Therapeutics Revenue and Competitors

Appili Therapeutics is building a team of drug development professionals dedicated to advancing novel therapeutics in the area of infectious disease. Formed in mid 2015 & backed by Bloom Burton & Co, Appili has commenced development on two anti-infective programs, while continuing its search for additional high quality anti-infective assets at all stages of development. The Company's ATI-1503 program is a novel class of 30S ribosome targeting agents that have demonstrated efficacy against three key Gram-negative ESCAPE pathogens (Klebsiella, Acinetobactor and Pseudomonas). Appili's medicinal chemistry effort continues to build on recent improvements in MIC (32→4ug/ml) and IC50 (1.7→0.34uM) that have demonstrated a strong structure/activity relationship that guides ongoing development. With a well characterized understanding of the novel mechanism of action, very low frequency of resistance, excellent solubility, PK and favourable toxicity profile ATI-1503 is well positioned to make significant progress in 2017. Appili's ATI-1501 program is a taste masked re-formulation of an existing marketed antibiotic that will be developed via the FDA's 505(b)(2) accelerated approval mechanism. Targeting C. difficile, Appili has received orphan designation and is continuing the clinical development of ATI-1501.